The Cancer Letter

Inside information on cancer research and drug development

Drugs & Targets

Soligenix to recruit patients for phase III study

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Soligenix Inc. will collaborate with the National Organization for Rare Disorders and the Cutaneous Lymphoma Foundation to recruit patients for its phase III clinical study of SGX301 (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account